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Abstract50
The aim of this study was to determine the impact of the carbapenemase-51
producing Enterobacteriaceae (CPE) in Spain in 2013 by describing their prevalence,52
dissemination and geographic distribution of CPE clones, their population structure and53
antibiotic susceptibility.54
From February 2013 to May 2013, 83 hospitals (about 40,000 hospital beds)55
prospectively collected non-duplicate Enterobacteriaceae using the screening cut-off56
recommended by EUCAST. Carbapenemase characterisation was performed by57
phenotypic methods and confirmed by PCR and sequencing. MLST types were58
determined for Klebsiella pneumoniae and Escherichia coli.59
A total of 702 Enterobacteriaceae isolates met the inclusion criteria; 379 (54%) were60
CPE. OXA-48 (71.5%) and VIM-1 (25.3%) were the most frequent carbapenemases,61
and K. pneumoniae (74.4%), Enterobacter cloacae (10.3%), and E. coli (8.4%) were the62
species most affected. Susceptibility to colistin, amikacin and meropenem was 95.5%,63
81.3%, and 74.7%, respectively. The most prevalent STs were ST11 and ST405 in K.64
pneumoniae, and ST131 in E. coli. Forty-five (54.1%) of the hospitals had at least one65
CPE case. In K. pneumoniae, ST11/OXA-48, ST15/OXA-48, ST405/OXA-48, and66
ST11/VIM-1 were detected in two or more Spanish provinces. ST11 carried four67
carbapenemases (VIM-1, OXA-48, KPC-2, and OXA-245), but ST405 carried OXA-4868
only.69
A wide interregional spread of CPE in Spain was observed mainly due to a few70
successful clones of OXA-48-producing K. pneumoniae (e.g. ST11 and ST405).71
Dissemination of OXA-48-producing E. coli is a new finding of public health concern.72
According to in vitro susceptibilities, most of the CPE (94.5%) had three or more73
options of antibiotic treatment.74
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Introduction75
Carbapenemase-producing Enterobacteriaceae (CPE), mainly Klebsiella76
pneumoniae, are an emerging threat to public and individual health worldwide. These77
microorganisms are often resistant to almost all available antibiotics (1,2), so there are78
few alternative treatment options. The most common carbapenemases are KPC (class79
A); VIM, IMP, and NDM (class B); and the OXA-48 types (class D). However, the80
extent to which healthcare systems have been affected, and the predominant81
carbapenemase types, differ substantially from country to country (3).82
A multicenter study performed in Spain in 2009 revealed 43 (0.04%) cases of83
CPE, which were mostly VIM-1 and IMP-22 (4). After that, we reported a rapid84
increase in the number of cases of CPE, mainly OXA-48-producing K. pneumoniae, in85
this country from 2010–2012 (5-7).86
Because previous studies (5,6) were based on voluntary reports without taking87
into account key important issues, in this manuscript we present data on the impact of88
CPE as obtained from a prospective, multicenter and population-based study. We show89
carbapenemase-production in this country is widely and irregularly distributed; however90
susceptibility rates to meropenem and colistin were still high so far.91
92
Material and methods93
Study design and bacterial isolates94
A prospective multicentre study was designed to identify Enterobacteriaceae95
isolates with decreased susceptibility to carbapenems. Isolates were collected from96
clinical infections and carriers between February and May, 2013. Eighty-three Spanish97
hospitals from 33 out of the 50 Spanish provinces participated in the study; these 3398
provinces belonged to 15 of the 17 Spanish Autonomous Communities. Eight of the99
hospitals acted as coordinating centers. The estimated catchment population was100
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approximately one-half of the Spanish population, and consisted of approximately 21.7101
million individuals and 40,100 hospital beds. The participating hospitals registered the102
total number of infections caused by Enterobacteriaceae during the study period so that103
the values for CPE prevalence could be estimated; presence of infections was104
established according to previously defined criteria (8).105
EUCAST screening cut-off values were used to identify CPE (9). The inclusion106
criteria were all Enterobacteriaceae isolates presenting either MICs >0.125 mg/L to107
meropenem and/or ertapenem and/or >1 mg/L to imipenem, or disk inhibition zones108
obtained using the disk diffusion method <25 mm to meropenem and/or ertapenem109
and/or <23 mm to imipenem. Only one isolate per patient and species was considered110
for further analysis. Isolates from the genera Proteus, Providencia, and Morganella that111
had reduced susceptibility to imipenem, but were susceptible to ertapenem and112
meropenem, were not included in the analysis; in addition, Enterobacter isolates that113
had reduced susceptibility to ertapenem, but were susceptible to imipenem and114
meropenem, were also excluded.115
116
Bacterial identification and drug-susceptibility testing117
The initial assays on the isolates were performed at each participating hospital,118
using standard microbiological methods. Each hospital also submitted their isolates to119
one of the eight coordinating centres, where carbapenemase production was confirmed120
using phenotypic and genotypic methods. Finally, all study isolates were submitted to121
the antibiotic laboratory of the Spanish National Centre of Microbiology, which acted as122
a central reference laboratory. All isolates meeting the phenotype inclusion criteria (9)123
were classified using the algorithm for phenotypic carbapenemase detection124
recommended by EUCAST (9). A modified Hodge test using a meropenem disk with125
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cloxacillin (600 µg) was performed on all isolates. In addition, inhibition of126
carbapenemase activity was carried out by comparing the inhibition zones obtained127
from meropenem disks, with or without EDTA (10 μL 0.5 M solution), phenyl-boronic 128
acid (400 µg), and cloxacillin (600 µg) in all isolates. Carba NP method was used as129
confirmatory test of carbapenemase activity when unclear phenotypic results or130
discrepancies between phenotypic and genotypic results, were observed (10).131
Antibiotic susceptibility testing was performed by disk-difussion and132
microdilution susceptibility methods according to EUCAST guidelines (11,12) in133
addition susceptibility to ertapenem, imipenem, meropenem and colistin were carried134
out by gradient test (bioMérieux, Marcy-l'Étoile, France).135
Extended spectrum β-lactamase (ESBL) production in OXA-48 and class B 136
carbapenemase producers was suspected if activity of cefotaxime or aztreonam,137
respectively, was recovered in presence of clavulanic acid. In the case of KPC-138
producers molecular characterization of ESBL genes were carried out in all isolates.139
140
Characterisation of resistance mechanisms141
The presence of genes encoding carbapenemases (blaOXA-48, blaKPC, blaVIM,142
blaIMP, and blaNDM) (5) and ESBLs (blaTEM, blaSHV, and blaCTX-M) (13) was determined143
using PCR and DNA sequencing assays.144
145
Molecular epidemiology146
MLST was performed for all carbapenemase-producing K. pneumoniae using147
the Institut Pasteur scheme148
(http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html; accessed149
January 2015). Carbapenemase-producing E. coli were typed by MLST using the150
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University of Warwick (Warwick Medical School, Coventry, UK) scheme151
(http://mlst.warwick.ac.uk; accessed January 2015). The phylogenetic relationships152
among the different sequence types (STs) found in this study were established153
according to the eBURST program version 3 (http://eburst.mlst.net).154
A simple diversity index (SD) previously described by Grundmann et al. (14)155
was applied to analyze the population diversity as follows: number of STs/total number156
of isolates x 100.157
We considered that two or more isolates of K. pneumoniae or Escherichia coli158
(including clinical cases and carriers) were epidemiologically related if they belonged to159
the same species, had the same MLST type, and produced the same carbapenemase160
type. For E. cloacae, this epidemiological association was established when the genetic161
linkage was >85% using PFGE after total chromosomal DNA digestion with XbaI (13).162
163
Statistical analysis164
Differences in the prevalence values for resistance mechanisms between the165
different groups were assessed using Fisher’s exact test. Associations were determined166
by calculating ORs with 95% CIs. The null hypothesis was rejected for values of P <167
0.05. Statistical analysis was performed using GraphPad Prism, version 3.02, software168
(GraphPad Software, Inc., San Diego, CA, USA).169
170
Results and Discussion171
Bacterial isolates and carbapenemases types172
A total of 702 Enterobacteriaceae isolates that were collected from an equal173
number of patients met the phenotypic criteria for inclusion; being K. pneumoniae174
(53.3%), E. cloacae (15.8%), and E. coli (13.8%) the most common species (Table 1).175
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Of these 702 isolates, 379 (54%) were confirmed as CPE and were distributed as176
follows: 282 (74.4%) were K. pneumoniae, 39 (10.3%) E. cloacae, 32 (8.4%) E. coli, 11177
(2.9%) Klebsiella oxytoca, 7 (1.8%) Citrobacter freundii, 4 (1.1%) Serratia178
marcescens, 2 (0.5%) Enterobacter aerogenes, 1 (0.3%) Morganella morganii, and 1179
(0.3%) isolate Enterobacter sp. (Table 1). The percentages of CPE isolates significantly180
varied between species as follows: 75.4% (282 of 374) of the K. pneumoniae, 35.1%181
(39 of 111) of the E. cloacae, and 33% (32 of 97) of the E. coli isolates; the percentage182
obtained for K. pneumoniae was significantly higher than those for E. cloacae and E.183
coli (P < 0.0001). In a recent French study, 1485 Enterobacteriaceae isolates non184
susceptible to carbapenems according EUCAST criteria were detected (42.2% and185
35.2% were Enterobacter spp. and K. pneumoniae, respectively); of them 340 (22.9%)186
isolates were carbapenemase producers (65.9% and 9.7% were K. pneumoniae and187
Enterobacter spp., respectively) (15).188
Of the 379 CPE isolates detected, 300 (79.2%) were isolated from clinical189
samples, and were mostly from urine (158, 52.7%), wound (59, 19.7%), respiratory (37,190
12.3%), and blood (28, 9.3%) samples. The remaining 79 CPE (20.2%) isolates were191
from screening samples (81% from rectal or perianal samples). In total, 193 CPE cases192
(50.9%) were isolated from males, and 239 (63.1%) were from patients >65 years of193
age.194
The carbapenemase types identified were: 271 (71.5%) OXA-48 group (258195
OXA-48 and 13 OXA-245), 96 (25.3%) VIM (95 VIM-1 and one VIM-2), 8 (2.1%)196
KPC-2, and 6 (1.6%) IMP (4 IMP-13 and two IMP-22). Each of two K. oxytoca isolates197
produced both KPC-2 and VIM-1, these two isolates came from two different hospitals198
from the Madrid area, and were isolated in March-2013 and May-2013. Isolates from199
carriers had the following carbapenemase types: 69.6% OXA-48 group, 30.3% VIM200
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group, and 1.3% KPC. K. pneumoniae was more prevalent among the OXA-48 isolates201
(86.7%) than among the VIM isolates (44.8%) (P < 0.0001). Comparison of OXA-48-202
group- and VIM-group-producing isolates is showed in Table 2.203
OXA-48 prevalence is also increasing in other European countries as France,204
Germany, Belgium, and the United Kingdom, where increasing numbers of outbreaks205
have been described (1,16-20). However, OXA-48 is rarely identified in North America206
(21). Compared with OXA-48 and VIM, KPC was identified very infrequently in this207
study. However, KPC-producing Enterobacteriaceae have already caused sporadic208
hospital outbreaks in Spain (3,22). KPC enzymes are endemic in other European209
countries, such as Greece and Italy (1,3,23), and it produces nosocomial outbreaks in210
North America (1). The number of carbapenemase-producing E. coli identified in this211
study was much higher than in previous studies (4,5). This remarkable finding is of212
serious concern because E. coli may facilitate the community spread of213
carbapenemases.214
ESBL production was detected in 267 of the 379 CPE (70.4%); 227 (85%)215
produced CTX-M-15, 16 (6%) SHV-12, 15 (5.6%) CTX-M-9, 9 (3.4%) SHV-134, 1216
(0.4%) produced CTX-M-14, and 1 (0.4%) produced CTX-M-1. Two CPE isolates had217
two different types of ESBLs. Carbapenemase-producing K. pneumoniae more218
frequently co-produced ESBLs (235 of 282 isolates, 83.3%) than did E. cloacae (18 of219
38 isolates, 47.4%) or E. coli (11 of 32, 34.4%) (P < 0.0001). Co-production of ESBLs220
occurred in the 90.6% and 28% of OXA-48-producing K. pneumonia and E. coli,221
respectively (P < 0.0001), mostly CTX-M-15. Potron et al. (24) found that co-222
production of OXA-48 and CTX-M-15 occurred in 41.7% of OXA-48-producing E. coli223
isolates from 10 different European and African countries. Five OXA-48- and SHV-12-224
producing K. pneumoniae belonged to ST147 were isolated in Asturias (northern225
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Spain). Associations between OXA-48 and ESBLs of the SHV-type have previously226
been infrequently reported (24).227
228
Antibiotic susceptibility testing.229
Overall the antibiotics showing the highest percentages of susceptibility were230
colistin (95.5%), amikacin (81.3%), meropenem (74.7%), tigecycline (71%), and231
imipenem (67.6%) (Table 3). However, antibiotic susceptibility significantly varied232
between the OXA-48-producing and VIM-producing isolates (Table 3), the VIM-233
producing isolates usually being more resistant.234
A total of 182 CPE (48%) were susceptible to colistin, amikacin, tigecycline,235
and carbapenems (imipenem or meropenem); of them, 107 were also susceptible to236
fosfomycin. According to previous clinical experience (2), use of a carbapenem237
(meropenem or imipenem) for the treatment of  a CPE with a MIC of ≤8 mg/L, in 238
combination with another active agent, seems reasonable; following this criteria, we239
identified 21 highly resistant CPE isolates (5.5%; 12 OXA-48 isolates, 8 VIM-1 and one240
KPC-2) presenting only one or two options to choose from for clinical purposes, mainly241
colistin and carbapenems (n=5) or colistin and tigecycline (n=5).242
243
Geographic distribution and prevalence of infections due to CPE in Spain.244
At least one case of CPE was identified at 45 (54.1%) of the 83 participating245
hospitals (Figure 1). These hospitals were located in 18 of the 33 (54.5%) participating246
provinces. In twenty one (46.7%) of the 45 hospitals with CPE isolates, potential247
outbreaks of epidemiological related CPE were detected affecting 209 (55.1%) of the248
379 CPE isolates included in this study.249
250
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Data about the total numbers of infections caused by Enterobacteriaceae during251
the study period were provided by 75 (90.4%) of the participating hospitals. A total of252
120,808 single infections by patient and specie were identified. The estimated overall253
prevalence of infection by carbapenemase-producing K. pneumoniae was 1.7%254
(231/13842; range: 0–11.6%), and 23 (30.7%) hospitals had a prevalence >1%. For255
Enterobacter spp. and E. coli, these figures were 0.5% (28/5085; range: 0–6.4%) and256
0.03% (28/91553; range: 0-0.4%), respectively. The prevalence of carbapenemase-257
production in K. pneumoniae and E. coli in a multicenter study performed in Spain in258
2009 was 0.2% and 0.001%, respectively (4).259
Although the number of OXA-48 producing isolates was greater than the260
number of VIM-producing isolates (271 vs. 96, Table 1), the VIM-producing isolates261
were more widely geographically distributed. VIM-producing isolates were detected in262
16 (40.5%) provinces and OXA-48-producing isolates were detected in 10 (30.3%).263
This finding could be related to the earlier detection of VIM in Spain that occurred in264
2005 (25), compared with OXA-48 in 2009 (26).265
266
Population structure of carbapenemase-producing K. pneumoniae and E. coli isolates267
causing clinical infections.268
Using MLST, 24 different sequence-types (ST) were identified among the 221269
carbapenemase-producing K. pneumoniae implicated in clinical infections (SD: 10.6;270
mean: 9.2 isolates per ST; range: 1–66). The most prevalent STs were ST11 (66271
isolates, 29.9%), ST405 (65, 29.4%), ST15 (28, 12.7%) and ST326 (15, 6.8%). These272
four STs were found in 78.8% of the carbapenemase-producing K. pneumoniae isolates.273
ST405 and ST11 clinical isolates were isolated in 18 different each one. ST11 carried274
four different types of carbapenemases (VIM-1, OXA-48, KPC-2, and OXA-245), but275
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ST405 carried only OXA-48. Analysis with eBURST provided an overview of STs of276
the Spanish carbapenemase producing K. pneumoniae isolates from this study compared277
with all K. pneumoniae isolates from the MLST database. The major ST found are278
represented in Figure 2. Excluding the isolates from this study, ST11 was the second279
most frequent ST in the MLST database (103 of 2405, 4.28%) and ST405 was280
uncommon (4 of 2405, 0.17%). In this eBurst analysis, ST405 was shown as a singleton281
non-related with other classical STs (Figure 2). These results suggest that K.282
pneumoniae belonging to ST11 and ST405 strongly contribute to the dissemination of283
OXA-48-producing Enterobacteriaceae in Spain. ST11 has been identified as an284
international high-risk clone associated ESBL- and carbapenemase production (27,28) ,285
but ST405 has recently been associated with OXA-48 production in Spain, Belgium,286
and France (5,6,17,18).287
Among the 27 carbapenemase-producing E. coli implicated in clinical infections,288
16 different STs were identified (SD: 59.3; mean: 1.7 isolates per ST; range: 1–7).289
ST131 (seven isolates, 26%) and ST156 (three isolates, 11.1%) were the most prevalent290
STs identified. These findings suggest that, compared with K. pneumoniae,291
carbapenemase-producing E. coli isolates may have a more diverse and polyclonal292
population structure, as previously demonstrated for other resistance mechanisms like293
ESBL (29). The acquisition of carbapenemases by the globally distributed E. coli294
ST131 that has been detected in this and other studies (30, 31) is a finding of serious295
concern. In a recent study of OXA-48-producing K. pneumoniae and E. coli in several296
European and north-African countries, the most common STs identified were ST101297
and ST38, respectively (24).298
299
Potential interregional spread of CPE strains.300
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One finding with epidemiological implications was that some of the more301
prevalent K. pneumoniae clones carrying carbapenemases were identified in more than302
one Spanish province suggesting that potential interregional spread of these clones may303
be occurred; however, the possibility of OXA-48 encoding plasmids acquisition by two304
isolates of a same prevalent ST from different regions cannot be excluded.305
ST405/OXA-48 was detected in six different Spanish provinces, ST15/OXA-48 in four,306
and ST11/OXA-48 and ST11/VIM-1 in three each one. This interregional spread clearly307
indicates that further progress has occurred since the “independent hospitals outbreak”308
stage described by Canton et al. in 2010 (1).309
In addition, these carbapenemase genes are plasmid encoded and therefore their310
spread is probably due to both the clonal dissemination of a few specific strains and the311
transmission of epidemic auto-transferred plasmids carrying them (1,6,22).312
313
Conclusions314
We found that there was a wide geographic distribution of CPE species, and a315
clear increasing trend in the number of infections caused to CPE in Spain. Two316
successful clones of K. pneumoniae (ST11 and ST405) carried mainly OXA-48, while317
ST15 more often carried VIM. Although still infrequent, detection of a polyclonal318
dissemination of OXA-48-producing E. coli has serious implications for public health.319
According to in vitro susceptibilities, most of the CPE (94.5%) had three or320
more options of antibiotic treatment.321
The spread of CPE in Spain affected at least 68% of all provinces with a322
potential interregional spread of CPE strains. This finding also suggests that the public323
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K. pneumoniae 374 (53.3) 92 (28.5) 282
(74.4)
235 (86.7) 43 (44.8) 3 (37.5) 1(16.7)
E. cloacae 111 (15.8) 72 (22.3) 39 (10.3) 5 (1.8) 29 (30.2) 1 (12.5) 4 (66.6)
E. coli 97 (13.8) 65 (20.1) 32 (8.4) 25 (9.2) 7 (7.3) 0 0
K. oxytoca 16 (2.3) 5 (1.5) 11 (2.9) 1 (0.4) 10* (10.4) 2*(25) 0
C. freundii 14 (2) 7 (2.2) 7 (1.8) 2 (0.7) 3 (3.1) 2 (25) 0
S. marcescens 13 (1.8) 9 (2.8) 4 (1.1) 3 (1.1) 1 (1) 0 0
E. aerogenes 34 (4.8) 32 (9.9) 2 (0.5) 0 2 (2.1) 0 0
M. morgannii 21 (3) 20 (6.2) 1 (0.3) 0 1 (1) 0 0
Enterobacter
spp.
5 (0.7) 4 (1.2) 1 (0.3) 0 0 0 1(16.7)
Other 17 (2.4) 17 (5.3) 0 0 0 0 0
Total 702 (100) 323 (100) 379 (100) 271 (100) 96 (100) 8 (100) 6 (100)
540
a CBP, carbapenemases541
*Two isolates producing both KPC and VIM carbapenemases.542
543
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Odds ratio 95% CI P value
Age > 65 years 187 (69) 32 (47.4) 2.47 1.54-3.97 0.0002
K. pneumoniae 235 (86.7) 43 (44.8) 8.05 4.72-13.72 <0.0001
ST11 79 (33.6) 4 (9.3) 4.94 1.70-14.31 <0.0001
ST405 73 (31.1) 0 39.35 3.39- 648.40 <0.0001
ST15 22 (9.4) 15 (34.9) 0.19 0.089-0.41 <0.0001
ST326 22 (9.4) 1 (2.3) 4.34 0.57-33.08 0.22
E. coli 25 (9.2) 7 (7.2) 1.31 0.55-3.13 0.67
E. cloacae 5 (1.8) 29 (29.9) 0.044 0.016-0.12 <0.0001






















Colistin 95.5 95.2 95.9 1
Amikacin 81.3 84.8 73.2 0.014
Meropenem 74.7 80 63.9 0.002
Tigecycline 71 72.6 67 0.30
Imipenem 67.6 74.8 49.5 <0.0001
Fosfomycin 48 44.8 57.7 0.03
Chloramphenicol 39.6 46.7 23.7 <0.0001
Gentamicin 33.2 37.4 22.7 0.008
Aztreonam 20.1 12.2 40.2 0.0001
Tobramycin 16.4 20.7 5.2 0.0002
Trimethoprim/sulfamethoxazole 16.1 13.7 18.6 0.25
Ciprofloxacin 12.7 9.3 23.7 0.0007
Ceftazidime 9.5 13.3 0 <0.0001
Cefotaxime 7.7 10.8 0 0.0001







FIGURE 1. Geographic distribution of carbapenemase types detected during a559
prospective multicentre study in Spain (February–May 2013).560
561
FIGURE 2. Population snapshot of sequence types (STs) of Klebsiella pneumoniae562
isolates from the multilocus sequence typing (MLST) database and STs carbapenemase-563
producing K. pneumoniae from this study considered altogether.564
565
Footnote: The most important ST complexes found in this study (ST11, ST405, ST15,566
and ST 326) are emphasised. Some STs with single isolates from the MLST database567
have been excluded from the image for easy viewing.568
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